1.Extending the stroke treatment window beyond DAWN in patients with very slow progressor type collaterals: How far can we go?
Igor PAGIOLA ; Olivier CHASSIN ; Sophie GALLAS ; Mariana Sarov RIVIERE ; Nicolas LEGRIS ; Cristian MIHALEA ; Jildaz CAROFF ; Leon IKKA ; Vanessa CHALUMEAU ; Guilherme Brasileiro de AGUIAR ; Augustin OZANNE ; Jacques MORET ; Christian DENIER ; Laurent SPELLE
Journal of Cerebrovascular and Endovascular Neurosurgery 2021;23(4):354-358
Five trials published in 2015 showed the benefit of endovascular thrombectomy (ET) in patients with stroke and large vessel occlusion, extending the treatment window has become an obsession of all physicians. In 2018, the DAWN and DEFUSE-3 trials showed that, with careful selection of patients, the procedure could be carried out up to 24 hours after symptom onset with good outcomes. In addition, there have been cases where the DAWN criteria were met, and treatment occurred >24 hours after symptom onset. We present the case of a 68-year-old female whose groin puncture occurred 52 hours after the time last known well (TLKW), after neurological worsening of the initial situation, with a large mismatch ratio observed on magnetic resonance imaging, achieving TICI (the Thrombolysis in Cerebral Infarction scale) grade 3 recanalization. Five days after the procedure, the patient was discharged with NIHSS (National Institutes of Health Stroke Scale) score of 3. Some types of collateral circulation (slow progressors and “turtle” progressors, our term for very slow progressors) can extend the treatment window beyond 24 hours of the TLKW but can lead to a hyperperfusion-like syndrome immediately after the ET. Further studies are needed to evaluate the reproducibility of this hypothetical syndrome.
2.Glucose-6-phosphate dehydrogenase (G6PD) deficiency is associated with asymptomatic malaria in a rural community in Burkina Faso.
Abdoul Karim OUATTARA ; Cyrille BISSEYE ; Bapio Valery Jean Télesphore Elvira BAZIE ; Birama DIARRA ; Tegwindé Rebeca COMPAORE ; Florencia DJIGMA ; Virginio PIETRA ; Remy MORET ; Jacques SIMPORE
Asian Pacific Journal of Tropical Biomedicine 2014;4(8):655-658
OBJECTIVETo investigate 4 combinations of mutations responsible for glucose-6-phosphate dehydrogenase (G6PD) deficiency in a rural community of Burkina Faso, a malaria endemic country.
METHODSTwo hundred individuals in a rural community were genotyped for the mutations A376G, G202A, A542T, G680T and T968C using TaqMan single nucleotide polymorphism assays and polymerase chain reaction followed by restriction fragment length polymorphism.
RESULTSThe prevalence of the G6PD deficiency was 9.5% in the study population. It was significantly higher in men compared to women (14.3% vs 6.0%, P=0.049). The 202A/376G G6PD A- was the only deficient variant detected. Plasmodium falciparum asymptomatic parasitaemia was significantly higher among the G6PD-non-deficient persons compared to the G6PD-deficient (P<0.001). The asymptomatic parasitaemia was also significantly higher among G6PD non-deficient compared to G6PD-heterozygous females (P<0.001).
CONCLUSIONSThis study showed that the G6PD A- variant associated with protection against asymptomatic malaria in Burkina Faso is probably the most common deficient variant.